Trial Profile
A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Aug 2021
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms REGARD
- Sponsors Eli Lilly and Company; ImClone Systems
- 25 Jan 2020 Results of pooled meta-analysis of REGARD, RAINBOW and RAINFALL phase III studies assesing impact of early weight loss on survival, presented at the 2020 Gastrointestinal Cancers Symposium
- 19 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 14 Dec 2018 European Union, Jordan, Malaysia were the planned locations for this trial.